How Heino was paid
$2.2M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Mary Anne HeinoExecutive Chairperson and Chief Executive Officer | $100,000 | $749,963 | $749,999 | — | $573,968 | $2,173,930 |
| Robert J. Marshall, Jr.Chief Financial Officer and Treasurer | $697,840 | $3,403,332 | $799,967 | $277,877 | $15,948 | $5,194,964 |
| Dr. Ludger DinkelborgHead of Research and Development | $227,716 | $799,968 | $799,985 | $13,410,752 | $21,176 | $15,259,597 |
| Amanda M. MorganChief Commercial Officer | $541,977 | $2,127,140 | $499,958 | $107,906 | $27,566 | $3,304,547 |
| Daniel M. NiedzwieckiChief Administrative Officer, General Counsel and Corporate Secretary | $588,816 | $3,403,332 | $799,967 | $156,860 | $17,409 | $4,966,384 |
| Brian A. MarkisonFormer Chief Executive Officer | $990,385 | $10,104,081 | $2,374,972 | $434,775 | $15,525 | $13,919,738 |
| Paul M. BlanchfieldFormer President | $693,333 | $3,828,938 | $899,970 | — | $13,034 | $5,435,275 |
What changed and why
- Mary Anne Heino served as Executive Chairperson and Interim CEO during 2025.
- Brian A. Markison served as CEO until his retirement on December 31, 2025.
- Dr. Ludger Dinkelborg joined as Head of Research and Development in August 2025.
- Products impacted the lives of nearly seven million patients in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.